Quince Therapeutics, Inc.
QNCX
$1.22
-$0.04-3.18%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.41% | -1.31% | -5.27% | 5.61% | 14.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.42% | 38.86% | 40.85% | 54.35% | 47.17% |
| Operating Income | -39.42% | -38.86% | -40.85% | -54.35% | -47.17% |
| Income Before Tax | -42.34% | -7.10% | 7.75% | -100.70% | -79.66% |
| Income Tax Expenses | 3,594.25% | -42.75% | 13.56% | 25.61% | 144.16% |
| Earnings from Continuing Operations | -47.78% | -6.97% | 7.71% | -100.49% | -81.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.78% | -6.97% | 7.71% | -100.49% | -81.07% |
| EBIT | -39.42% | -38.86% | -40.85% | -54.35% | -47.17% |
| EBITDA | -39.75% | -40.58% | -42.15% | -55.72% | -48.36% |
| EPS Basic | -25.04% | 2.14% | 13.38% | -83.89% | -56.04% |
| Normalized Basic EPS | -78.07% | -57.14% | -61.07% | -50.95% | -35.79% |
| EPS Diluted | -25.04% | 2.14% | 13.38% | -83.89% | -56.04% |
| Normalized Diluted EPS | -78.07% | -57.14% | -61.07% | -50.95% | -35.79% |
| Average Basic Shares Outstanding | 15.73% | 10.54% | 8.73% | 11.43% | 16.16% |
| Average Diluted Shares Outstanding | 15.73% | 10.54% | 8.73% | 11.43% | 16.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |